Galapagos has discovered drug targets (starting points for the development of novel drugs) using cells from patients for more than fifteen diseases. These targets form the basis of drug discovery programs aimed at identifying small molecules or antibodies that alter the activity of these proteins, thereby potentially changing the course of the disease. By studying the disease process and key points of intervention, it is our goal to develop new drugs that stop the disease rather than just treat the symptoms.
In 2008, Galapagos began to pursue drug discovery and development in orphan diseases – diseases of high medical need, not commonly pursued by pharmaceutical companies. Cystic fibrosis (CF) is the first orphan disease in which Galapagos plans to discover, develop and launch disease-modifying medicines. In September 2013, Galapagos and AbbVie signed a collaborative agreement by which both companies will fund and contribute science toward discovering novel small molecule therapies for the largest mutations in CF. Click here (link to CF page) for more information on our CF programs.
In November 2008, Galapagos and MorphoSys initiated an alliance to co-develop novel therapeutic antibodies in bone & joint disease. The partners combine their proprietary drug targets and unique technologies to discover and develop antibody therapies based on novel modes of action in bone & joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. Both companies will share the research and development costs, as well as all future revenues equally.
Antibodies with high specificity towards the first target have been generated and are now being tested in disease-specific experiments. In parallel, Galapagos has applied its target discovery platform to identify additional targets for antibody development.
Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins
Douglas Macdonald, Michela A. Tessari, Ivette Boogaard, Melanie Smith, Kristiina Pulli, Agnieszka Szynol, Faywell Albertus, Marieke B. A. C. Lamers, Sipke Dijkstra, Daniel Kordt, Wolfgang Reindl, Frank Herrmann, George McAllister, David F. Fischer, Ignacio Munoz-Sanjuan
PLoS ONE 9(5): e96854. doi:10.1371/journal.pone.0096854
Biology calls the targets: combining RNAi and disease biology
van Es HH, Arts GJ
Drug Discov Today 2005 Oct 15;10(20):1385-91
Functional screening of viral siRNA libraries in human primary cells
Bortone K, Michiels F, Vandeghinste N, Tomme P, and van Es H.
Drug Discov World 2004 Fall:20-27
Adenoviral vectors expressing siRNAs for discovery and validation of gene function
Arts GJ, Langemeijer E, Tissingh R, Ma L, Pavliska H, Dokic K, Dooijes R, Mesic E, Clasen R, Michiels F, van der Schueren J, Lambrecht M, Herman S, Brys R, Thys K, Hoffmann M, Tomme P, van Es H
Genome Res. 2003 Oct;13(10):2325-32
Arrayed adenoviral expression libraries for functional screening
Michiels F, van Es H, van Rompaey L, Merchiers P, Francken B, Pittois K, van der Schueren J, Brys R, Vandersmissen J, Beirinckx F, Herman S, Dokic K, Klaassen H, Narinx E, Hagers A, Laenen W, Piest I, Pavliska H, Rombout Y, Langemeijer E, Ma L, Schipper C, Raeymaeker MD, Schweicher S, Jans M, van Beeck K, Tsang IR, van de Stolpe O, Tomme P, Arts GJ, Donker J
Nat Biotechnol. 2002 Nov;20(11):1154-7. Erratum in: Nat Biotechnol. 2003 Feb;21(2):199